VIR BIOTECHNOLOGY INC (VIR) Stock News

NASDAQ:VIR - US92764N1028 - Common Stock

4.94 USD

-0.1 (-1.98%)

Last: 8/29/2025, 8:00:02 PM

5 USD

+0.06 (+1.21%)

After Hours: 8/29/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

VIR Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Benzinga - Mentions: DSP MRVL CRWV KARO ...

This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

a day ago - By: Benzinga - Mentions: DLTR MRVL SWX CRWV

This Southwest Gas Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday

4 days ago - By: Yahoo Finance - Mentions: LLY HSBC SBAC T-PA ...

Micron initiated, Eli Lilly upgraded: Wall Street's top analyst calls

24 days ago - By: The Motley Fool

Vir (VIR) Q2 Revenue Drops 61%

5 days ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

24 days ago - By: Zacks Investment Research - Mentions: FEMY

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

24 days ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

25 days ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

a month ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

a month ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

a month ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

3 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

3 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

4 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

4 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

4 months ago - By: Zacks Investment Research - Mentions: AGEN

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates

4 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

4 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

4 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

5 months ago - By: Yahoo Finance - Mentions: IOVA DAWN ARVN NUVB ...

Iovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will Triple

5 months ago - By: Yahoo Finance - Mentions: RLAY KIND GOSS DAWN ...

Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple

5 months ago - By: Yahoo Finance - Mentions: GOSS PRLD DAWN NUVB ...

Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple

5 months ago - By: Yahoo Finance - Mentions: NUVB RLAY TSLA DAWN ...

Nuvation Bio Inc. (NUVB): Among Stocks Under $10 that Will Triple

5 months ago - By: Yahoo Finance - Mentions: ARVN DAWN WMT NUVB ...

Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple

5 months ago - By: Yahoo Finance

Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple

5 months ago - By: Brii Biosciences Limited

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results